65,437 trials
Restless Legs Syndrome
Primary: Number of Subjects for Which the Clinician Reported "Much Improved" or "Very Much Improved" on the Clinical Global Impressions-Improvement (CGI-I) Scale in Treatment…
Healthy
Primary: Concentration of Total Plasma Amino Acids — 2730.87; 2988.94; 2964.19; 2869.14 umol/mL
Breast Cancer · Breast Tumors · Metastatic Cancer
Primary: Progression Free Survival (PFS) — 3.9; 5.7 Months
Anesthetics, Local
Primary: Time to Return to Baseline Sensation, as Determined by Binary Outcomes (Yes/no) in 15 Minute Increments — 54.34; 49.86; 43.13; 55.78 Minutes — p=0.93
Parenteral Nutrition Associated Liver Disease · Short Bowel Syndrome · Gastrointestinal Disease
Primary: Reversal of Cholestasis, Defined as a Direct Bilirubin to <= 2.0 mg/dL. — 11.7; 6.4 Weeks — p==0.001
Healthy
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Rosuvastatin — 9.45; 23.0; 23.0 nanograms per milliliter (ng/mL)
Cardiac Arrest
Primary: Sensitivity — 1012 Participants
Paroxysmal Atrial Fibrillation · Persistent Atrial Fibrillation · Cardiac Arrhythmia
Primary: Percentage of Subjects With One-year Success — 57.2 percentage of participants
Anhedonia
Primary: Change in Anhedonic (Snaith-Hamilton Pleasure Scale; SHAPS) Symptoms — 7.06; -1.29 units on SHAPS scale
Glaucoma
Primary: Intraocular Pressure (IOP) — 21.7; 22.4; 14.9; 12.6 mmHg — p=0.687
Tourette Syndrome
Primary: Number of Participants With a 40% Reduction in Total Tics on the Yale Global Tic Severity Scale (YGTSS) With CDBS (Period 1) — 4 Participants — p=0.05
Obstructive Sleep Apnea
Primary: Nocturnal Heart Rate (Beats/Min, BPM) — 64.1; 60.2 BPM
Orthopedic Disorder
Primary: Compliance to Prescribed Use — 67.7; 83.3 percentage of prescribed use/24hr
Presbyopia
Primary: Proportion of Subjects With >=15 Letter Gain Without >=5 Letter Loss in Near Visual Acuity — 49.4; 35.0; 22.7 Percentage of participants — p=<.001
Depressive Disorder, Major · Bipolar Disorder · Schizo Affective Disorder
Primary: Acceptance of Intervention-Number of Participants Who Dropped Out of Treatment — 4; 3 Participants